Exelon Patch 10 Transdermal Flaster

Description

Exelon Patch 10, a transdermal therapeutic system containing the active substance rivastigmine, is a widely used intervention in the treatment of mild to moderate dementia related to Alzheimer’s and Parkinson’s diseases. The patch, which measures 10 cm², continuously delivers a dose of 9.5 mg of rivastigmine over a 24-hour period. This method ensures a steady concentration of the medication in the bloodstream, which helps reduce the likelihood of gastrointestinal side effects often experienced with oral cholinesterase inhibitors.

Its non-invasive application and stable pharmacokinetics make it an especially suitable option for elderly patients or those who struggle with swallowing pills.

Pharmacological Action

Rivastigmine, the active ingredient in Exelon Patch 10, is classified as a cholinesterase inhibitor. It functions by reversibly inhibiting two key enzymes: acetylcholinesterase and butyrylcholinesterase. These enzymes are involved in the breakdown of acetylcholine, a neurotransmitter that plays a critical role in processes related to memory, learning, and attention.

In patients suffering from dementia, acetylcholine levels are significantly reduced, leading to a progressive decline in cognitive function. By blocking these enzymes, rivastigmine allows for higher acetylcholine levels in the brain, enhancing neural communication and providing temporary symptomatic relief. This mechanism helps stabilize or slow cognitive deterioration in dementia patients, thereby improving their ability to perform daily activities.

Therapeutic Indications

Exelon Patch 10 is clinically indicated for:

• The symptomatic treatment of mild to moderate dementia of the Alzheimer’s type.
• The treatment of mild to moderate dementia associated with Parkinson’s disease.
• Adjunctive care in comprehensive dementia treatment plans where pharmacological and non-pharmacological therapies are combined.

Dosing and Administration

Initiation and Titration

Therapy with Exelon typically begins with the lower-dose Exelon Patch 4.6 mg/24 h, allowing clinicians to assess patient tolerance and minimize adverse reactions. After a minimum period of four weeks, and if the initial dose is well-tolerated, patients may be transitioned to the Exelon Patch 10, which delivers 9.5 mg of rivastigmine over 24 hours. The therapeutic benefits often become more noticeable at this maintenance dose.

Application Protocol

• Only one patch should be applied per day, and it must be replaced after 24 hours.
• Approved application areas include the upper back, lower back, chest, and upper arm.
• To prevent skin irritation, rotate application sites daily and avoid using the same location within a 14-day period.
• Skin should be clean, dry, intact, and free of hair and irritation before applying the patch.

Missed Dose or Interruption

If a patch is not applied at the scheduled time, apply a new one immediately and resume the normal dosing schedule. If treatment is interrupted for more than three consecutive days, the therapy must be reinitiated at the lower 4.6 mg/24 h dose under clinical supervision to reduce the risk of adverse effects.

Composition

Each Exelon Patch 10 (10 cm²) includes:

• Active Ingredient: Rivastigmine 18 mg (providing a therapeutic delivery of 9.5 mg over 24 hours)
• Excipients: Tocopherol (vitamin E), silicone adhesive matrix, acrylic copolymers, dimethicone, and other pharmacologically inert excipients engineered to maintain structural integrity and facilitate transdermal absorption.

Precautions and Monitoring

• Initiation and dose escalation should be managed by healthcare professionals experienced in dementia treatment.
• Regular monitoring is advised during treatment initiation and dose adjustments to identify side effects early.
• Routine skin assessments are recommended, especially in patients with known dermal sensitivity.

Contraindications

• Known hypersensitivity to rivastigmine, other carbamate derivatives, or any patch excipients.
• Patients with severe hepatic impairment should not use Exelon Patch 10 due to altered metabolism and increased risk of toxicity.

Special Populations

• Geriatric Use: Frequently prescribed to elderly patients; requires careful titration and monitoring.
• Pediatrics: Safety and efficacy have not been established in individuals under 18 years of age.
• Pregnancy and Lactation: Use is not routinely recommended unless the potential benefit to the mother outweighs the risk to the fetus. There is insufficient data regarding excretion in human milk.

Side effects

Side effects are more frequently reported during initial dosing or following dose increases.

Common Side effects

• Gastrointestinal: Nausea, vomiting, diarrhea, anorexia, weight loss, and abdominal discomfort.
• Dermatologic: Erythema, pruritus, contact dermatitis, or rash at the application site.
• Neurological: Headache, dizziness, tremor, drowsiness, and instability during ambulation.
• Psychiatric: Confusion, insomnia, anxiety, restlessness, and depressive mood.

Serious Reactions

• Cardiac arrhythmias such as bradycardia, episodes of syncope, hallucinations, seizures, and rare but severe skin reactions including Stevens-Johnson Syndrome.

Safe Use Guidelines

• Never apply more than one patch at a time.
• Avoid applying the patch to skin that is red, irritated, or broken.
• Ensure loose-fitting clothing over the application site to avoid dislodgement.
• In the event of accidental contact with another person’s skin, remove the patch immediately and consult a healthcare provider.
• Used patches should be disposed of safely and kept out of reach of children and pets, as residual medication remains active.

Duration of Therapy

Exelon Patch 10 is intended for long-term use in the management of chronic cognitive disorders. Treatment duration is determined based on the clinical response and tolerability in the individual patient. Regular follow-up evaluations with the prescribing physician are crucial to determine ongoing benefit and to make any necessary adjustments in therapy. Discontinuation should always occur under medical guidance.

Drug Interactions

Clinicians should be cautious of potential drug interactions with rivastigmine:

• May antagonize the effects of anticholinergic agents.
• Can potentiate bradycardia when used in combination with beta-blockers.
• Concurrent use with metoclopramide may elevate the risk of developing extrapyramidal symptoms.

Patients must inform healthcare providers of all prescription medications, over-the-counter drugs, and herbal supplements they are using to avoid adverse interactions.

Clinical Utility Table

Conclusion

Exelon Patch 10 offers a reliable, non-invasive therapeutic option for patients with dementia-related cognitive decline. Its transdermal system enables steady delivery of medication, leading to improved tolerability and reduced systemic side effects. For patients who cannot tolerate or are non-compliant with oral therapies, the patch provides a more manageable and effective alternative.

While it does not alter the disease course, it significantly enhances symptom management and supports better functional outcomes when integrated into a comprehensive treatment regimen. Regular monitoring and individualized dose adjustments are essential to maximize the clinical benefit. Consultation with a healthcare professional is always necessary to ensure safe and effective use of Exelon Patch 10.